Role of prostate-specific antigen change ratio at initial biopsy as a novel decision-making marker for repeat prostate biopsy

Korean Journal of Urology

Volumn 53, Issue 7, 2012, Pages 467-471

  Lee, Jung Gon ^a   Bae, Seong Ho ^a   Choi, Seock Hwan ^a   Kwon, Tae Gyun ^a   Kim, Tae Hwan ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Prostate specific antigen; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; DECISION MAKING; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY;

EID: 84864803300     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.7.467     Document Type: Article

References (24)

1. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
2. Lin TP, Huang WJ, Chen KK. Differentiation of benign prostatic hyperplasia from prostate cancer using prostate specific antigen dynamic profile after transrectal prostate biopsy. J Urol 2004;171(6 Pt 1):2226-9.
3. Choi SH, Yoo ES, Park YI. The significance of prostate-specific antigen after transrectal prostate biopsy. Korean J Urol 2006; 47:958-62.
4. Song C, Ahn H, Lee MS, Park J, Kwon TG, Kim HJ, et al. Mass screening for prostate cancer in Korea: a population based study. J Urol 2008;180:1949-52.
5. Postma R, Schroder FH. Screening for prostate cancer. Eur J Cancer 2005;41:825-33.
6. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-23.
7. Devonec M, Fendler JP, Monsallier M, Mouriquand P, Mestas JL, Dutrieux-Berger N, et al. Prostatic cancer diagnosis with ultrasonically guided prostatic biopsy: results in 226 cases. Prog Clin Biol Res 1989;303:35-40.
8. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
9. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpoint of 2.5 ng/ml for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005;65:549-53.
10. Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: indications and technique. J Urol 2003;169:12-9.
11. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol 1999;162:293-306.
12. Partin AW, Oesterling JE. The clinical usefulness of percent free-PSA. Urology 1996;48(6A Suppl):1-3.
13. Schroder FH, Roobol MJ, van der Kwast TH, Kranse R, Bangma CH. Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 2006;49:460-5.
14. Filella X, Alcover J, Molina R, Rodriguez A, Carretero P, Ballesta AM. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer. Eur J Cancer 1997;33:1226-9.
15. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulman CC, et al. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999;54:517-22.
16. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159:1247-50.
17. Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 2001;165:1554-9.
18. Chon CH, Lai FC, McNeal JE, Presti JC Jr. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol 2002;167:2457-60.
19. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-8.
20. Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 2001;166:866-70.
21. Horinaga M, Nakashima J, Ishibashi M, Oya M, Ohigashi T, Marumo K, et al. Clinical value of prostate specific antigen based parameters for the detection of prostate cancer on repeat biopsy: the usefulness of complexed prostate specific antigen adjusted for transition zone volume. J Urol 2002;168:986-90.
22. Charrie A, Fleury-Goyon MC, Dutey P, Perrin P. The effect of prostate aspiration biopsy on serum levels of prostatic acid phosphatase and prostate-specific antigen. JAMA 1986;256:474.
23. Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992;147(3 Pt 2):810-4.
24. Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol 1997;157:195-8.